ReviewTargeted oncology2023
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Review in Targeted oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy.Cancers · 2026Review
- Observational
- Safety and efficacy of darolutamide in combination with androgen-deprivation therapy for prostate cancer: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Article
- GATA2 up-regulation restores androgen receptor chromatin association and advances darolutamide resistance in prostate cancer.Genes & diseases · 2025Article
- Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.International journal of urology : official journal of the Japanese Urological Association · 2025Review
- Efficacy and safety of darolutamideFrontiers in pharmacology · 2025Article
- Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models.International journal of molecular sciences · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Darolutamide (NUBEQA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.